Movatterモバイル変換

[0]ホーム
URL:

MX370788B - Cd33 specific chimeric antigen receptors for cancer immunotherapy. - Google Patents

Cd33 specific chimeric antigen receptors for cancer immunotherapy.

Info

Publication number
MX370788B
MX370788BMX2016012855AMX2016012855AMX370788BMX 370788 BMX370788 BMX 370788BMX 2016012855 AMX2016012855 AMX 2016012855AMX 2016012855 AMX2016012855 AMX 2016012855AMX 370788 BMX370788 BMX 370788B
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptors
cancer immunotherapy
specific chimeric
leukemia
Prior art date
Application number
MX2016012855A
Other languages
Spanish (es)
Other versions
MX2016012855A (en
Inventor
Galetto Roman
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=50486692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370788(B)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CellectisfiledCriticalCellectis
Publication of MX2016012855ApublicationCriticalpatent/MX2016012855A/en
Publication of MX370788BpublicationCriticalpatent/MX370788B/en

Links

Classifications

Landscapes

Abstract

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD33 monoclonal antibody, conferring specific immunity against CD33 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
MX2016012855A2014-04-032015-04-02Cd33 specific chimeric antigen receptors for cancer immunotherapy.MX370788B (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
DKPA2014701712014-04-03
PCT/EP2015/057331WO2015150526A2 (en)2014-04-032015-04-02Cd33 specific chimeric antigen receptors for cancer immunotherapy

Publications (2)

Publication NumberPublication Date
MX2016012855A MX2016012855A (en)2016-12-12
MX370788Btrue MX370788B (en)2020-01-06

Family

ID=50486692

Family Applications (1)

Application NumberTitlePriority DateFiling Date
MX2016012855AMX370788B (en)2014-04-032015-04-02Cd33 specific chimeric antigen receptors for cancer immunotherapy.

Country Status (13)

CountryLink
US (3)US9944702B2 (en)
EP (1)EP3126390B1 (en)
JP (1)JP6673848B2 (en)
KR (1)KR102170533B1 (en)
CN (1)CN106795221B (en)
AU (1)AU2015239069B2 (en)
CA (1)CA2944528C (en)
DK (1)DK3126390T3 (en)
ES (1)ES2765710T3 (en)
IL (1)IL247917B (en)
MX (1)MX370788B (en)
RU (1)RU2701341C2 (en)
WO (1)WO2015150526A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US10689609B2 (en)2012-03-152020-06-23Flodesign Sonics, Inc.Acoustic bioreactor processes
US9950282B2 (en)2012-03-152018-04-24Flodesign Sonics, Inc.Electronic configuration and control for acoustic standing wave generation
US9752113B2 (en)2012-03-152017-09-05Flodesign Sonics, Inc.Acoustic perfusion devices
US10322949B2 (en)2012-03-152019-06-18Flodesign Sonics, Inc.Transducer and reflector configurations for an acoustophoretic device
US9745548B2 (en)2012-03-152017-08-29Flodesign Sonics, Inc.Acoustic perfusion devices
US10704021B2 (en)2012-03-152020-07-07Flodesign Sonics, Inc.Acoustic perfusion devices
US10967298B2 (en)2012-03-152021-04-06Flodesign Sonics, Inc.Driver and control for variable impedence load
US9458450B2 (en)2012-03-152016-10-04Flodesign Sonics, Inc.Acoustophoretic separation technology using multi-dimensional standing waves
US10737953B2 (en)2012-04-202020-08-11Flodesign Sonics, Inc.Acoustophoretic method for use in bioreactors
US9745569B2 (en)2013-09-132017-08-29Flodesign Sonics, Inc.System for generating high concentration factors for low cell density suspensions
WO2015105955A1 (en)2014-01-082015-07-16Flodesign Sonics, Inc.Acoustophoresis device with dual acoustophoretic chamber
MX370788B (en)*2014-04-032020-01-06CellectisCd33 specific chimeric antigen receptors for cancer immunotherapy.
AU2015248956B2 (en)*2014-04-142020-06-25CellectisBCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
US9744483B2 (en)2014-07-022017-08-29Flodesign Sonics, Inc.Large scale acoustic separation device
WO2016014576A1 (en)2014-07-212016-01-28Novartis AgTreatment of cancer using a cd33 chimeric antigen receptor
US11377651B2 (en)2016-10-192022-07-05Flodesign Sonics, Inc.Cell therapy processes utilizing acoustophoresis
US11021699B2 (en)2015-04-292021-06-01FioDesign Sonics, Inc.Separation using angled acoustic waves
US11708572B2 (en)2015-04-292023-07-25Flodesign Sonics, Inc.Acoustic cell separation techniques and processes
US11474085B2 (en)2015-07-282022-10-18Flodesign Sonics, Inc.Expanded bed affinity selection
US11459540B2 (en)2015-07-282022-10-04Flodesign Sonics, Inc.Expanded bed affinity selection
AU2016337525B2 (en)2015-10-162022-01-20The Trustees Of Columbia University In The City Of New YorkCompositions and methods for inhibition of lineage specific antigens
CA3018382A1 (en)*2016-03-292017-10-05University Of Southern CaliforniaChimeric antigen receptors targeting cancer
US11085035B2 (en)2016-05-032021-08-10Flodesign Sonics, Inc.Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en)2016-05-032022-01-04Flodesign Sonics, Inc.Concentration and washing of particles with acoustics
WO2017214333A1 (en)*2016-06-082017-12-14Intrexon CorporationCd33 specific chimeric antigen receptors
JP2020513248A (en)2016-10-192020-05-14フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． Affinity cell extraction by sound
TW201829463A (en)2016-11-182018-08-16瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof
CA3054808A1 (en)2017-02-282018-09-07Vor Biopharma, Inc.Compositions and methods for inhibition lineage specific proteins
AU2018240556B2 (en)*2017-03-242025-02-27Lentigen Technology, Inc.Compositions and methods for treating cancer with anti-CD33 immunotherapy
CN110753555A (en)2017-04-192020-02-04得克萨斯州大学系统董事会Immune cells expressing engineered antigen receptors
KR20190140943A (en)*2017-04-242019-12-20메모리얼 슬로안 케터링 캔서 센터 Anti-CD33 Antibody Formulations
CN111406068A (en)2017-05-162020-07-10约翰霍普金斯大学 MANAbody and how to use it
JP7252651B2 (en)*2017-07-202023-04-05エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Compositions and methods for targeting CD33-expressing cancers
WO2019067677A1 (en)2017-09-292019-04-04Cell Design Labs, Inc.Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
US12053490B2 (en)2017-10-262024-08-06St. Jude Children's Research Hospital, Inc.Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
GB201719646D0 (en)*2017-11-272018-01-10Bivictrix Therapeutics LtdTherapy
EP3720559A4 (en)*2017-12-042021-10-06Actinium Pharmaceuticals, Inc. METHOD OF TREATMENT OF PATIENTS WITH MYELODYLOPLASTIC SYNDROMS
CN111480345B (en)2017-12-142022-04-29弗洛设计声能学公司Acoustophoretic system, method for operating acoustophoretic system, and method for controlling acoustic transducer and acoustic system
CN108047333B (en)*2018-01-152021-05-25浙江阿思科力生物科技有限公司 Specific antibodies targeting CD33, CAR-NK cells and their preparation and application
CA3093567A1 (en)*2018-03-142019-09-19The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesAnti-cd33 chimeric antigen receptors and their uses
WO2019183389A1 (en)2018-03-232019-09-26Kite Pharma, Inc.Chimeric transmembrane proteins and uses thereof
US10869888B2 (en)2018-04-172020-12-22Innovative Cellular Therapeutics CO., LTD.Modified cell expansion and uses thereof
AR114789A1 (en)2018-04-182020-10-14Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
AR115052A1 (en)*2018-04-182020-11-25Hoffmann La Roche MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM
CN110551741A (en)*2018-06-012019-12-10上海恒润达生生物科技有限公司Chimeric antigen receptor targeting CD33 and uses thereof
JP2021525534A (en)*2018-06-042021-09-27プレシゲン，インコーポレイテッド MUC16-specific chimeric antigen receptors and their use
EP3806888B1 (en)2018-06-122024-01-31Obsidian Therapeutics, Inc.Pde5 derived regulatory constructs and methods of use in immunotherapy
US11708401B2 (en)2018-06-222023-07-25Kite Pharma, Inc.Chimeric transmembrane proteins and uses thereof
CN110856724B (en)*2018-08-242022-05-27杭州康万达医药科技有限公司 Therapeutic agents comprising nucleic acid and CAR-modified immune cells and applications thereof
SG11202101994XA (en)2018-08-282021-03-30Vor Biopharma IncGenetically engineered hematopoietic stem cells and uses thereof
US12240915B2 (en)2018-08-302025-03-04Innovative Cellular Therapeutics Holdings, Ltd.Chimeric antigen receptor cells for treating solid tumor
EP3849565A4 (en)*2018-09-122022-12-28Fred Hutchinson Cancer Research Center REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
US20210386788A1 (en)2018-10-242021-12-16Obsidian Therapeutics, Inc.Er tunable protein regulation
CA3118816A1 (en)*2018-11-072020-05-14Crispr Therapeutics AgAnti-cd33 immune cell cancer therapy
WO2020123947A1 (en)2018-12-142020-06-18Bluebird Bio, Inc.Dimerizing agent regulated immunoreceptor complexes
SG11202107639UA (en)*2019-01-162021-08-30Univ ColumbiaCompositions and methods for inhibition of lineage specific antigens
WO2020219425A1 (en)*2019-04-252020-10-29Seattle Children's Hospital (dba Seattle Children's Research Institute)Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
CA3133333A1 (en)2019-04-302020-04-30Brian Scott GARRISONChimeric receptors and methods of use thereof
CN114206928B (en)*2019-05-082025-08-08印希彼生物科学公司 CD33-targeted immunotherapy
AU2020296878B2 (en)2019-06-212023-04-20Kite Pharma, Inc.TGF-beta receptors and methods of use
WO2021046451A1 (en)2019-09-062021-03-11Obsidian Therapeutics, Inc.Compositions and methods for dhfr tunable protein regulation
US12076343B2 (en)2020-02-192024-09-03Innovative Cellular Therapeutics Holdings, Ltd.Engineered safety in cell therapy
JP2023520409A (en)*2020-03-312023-05-17フレッド ハッチンソン キャンサー センター Chimeric antigen receptor targeting CD33
US12043654B2 (en)2020-06-022024-07-23Innovative Cellular Therapeutics Holdings, Ltd.Anti-GCC antibody and CAR thereof for treating digestive system cancer
CN116635064A (en)2020-12-182023-08-22世纪治疗股份有限公司 A chimeric antigen receptor system with adaptive receptor specificity
WO2022266075A1 (en)2021-06-142022-12-22Caribou Biosciences, Inc.Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
CN113527435B (en)*2021-07-142022-06-07呈诺再生医学科技(珠海横琴新区)有限公司Novel polypeptide for specifically identifying prostate cancer cells, derivatives and application thereof
GB202204386D0 (en)*2022-03-282022-05-11Cambridge Entpr LtdEngineered immune cell platform
WO2025008108A1 (en)2023-07-062025-01-09Miltenyi Biotec B.V. & Co. KGImmune cell expressing chimeric antigen receptor and transgenic t cell receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040049014A1 (en)1988-12-282004-03-11Protein Design Labs, Inc.Humanized immunoglobulins
PT659439E (en)*1993-12-242002-04-29Merck Patent Gmbh IMUNOCONJUGADOS
PT1578446E (en)2002-11-072015-07-22Immunogen IncAnti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
DE102009045006A1 (en)2009-09-252011-04-14Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
DK2496698T3 (en)*2009-11-032019-04-15Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
PH12013501201A1 (en)*2010-12-092013-07-29Univ PennsylvaniaUse of chimeric antigen receptor-modified t cells to treat cancer
US9447194B2 (en)*2012-02-132016-09-20Seattle Children's HospitalBispecific chimeric antigen receptors and encoding polynucleotides thereof
US20130309223A1 (en)2012-05-182013-11-21Seattle Genetics, Inc.CD33 Antibodies And Use Of Same To Treat Cancer
ES2962571T3 (en)2012-05-252024-03-19Cellectis Methods to modify allogeneic and immunosuppression-resistant T cells for immunotherapy
MX370788B (en)*2014-04-032020-01-06CellectisCd33 specific chimeric antigen receptors for cancer immunotherapy.
AU2015248956B2 (en)*2014-04-142020-06-25CellectisBCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy

Also Published As

Publication numberPublication date
CN106795221B (en)2022-06-07
DK3126390T3 (en)2020-01-20
RU2016143155A (en)2018-05-04
US20170145094A1 (en)2017-05-25
US9944702B2 (en)2018-04-17
RU2016143155A3 (en)2018-10-23
EP3126390B1 (en)2019-10-16
AU2015239069B2 (en)2020-02-20
US20240182565A1 (en)2024-06-06
JP2017515460A (en)2017-06-15
AU2015239069A1 (en)2016-10-06
WO2015150526A2 (en)2015-10-08
ES2765710T3 (en)2020-06-10
KR102170533B1 (en)2020-10-27
EP3126390A2 (en)2017-02-08
BR112016022369A2 (en)2017-10-10
JP6673848B2 (en)2020-03-25
CA2944528A1 (en)2015-10-08
IL247917A0 (en)2016-11-30
IL247917B (en)2020-11-30
CN106795221A (en)2017-05-31
KR20170002412A (en)2017-01-06
MX2016012855A (en)2016-12-12
CA2944528C (en)2021-08-10
RU2701341C2 (en)2019-09-25
US20190002561A1 (en)2019-01-03
WO2015150526A3 (en)2015-11-26

Similar Documents

PublicationPublication DateTitle
MX2016012855A (en)Cd33 specific chimeric antigen receptors for cancer immunotherapy.
MX2019012244A (en)Cd123 specific chimeric antigen receptors for cancer immunotherapy.
MX381908B (en) ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY.
MX2017001211A (en) RECEIVERS OF CHEMICAL ANTIGENS ROR1 (NTRKR1) SPECIFICS FOR CANCER IMMUNOTHERAPY.
MX2019001184A (en)Anti-idiotypic antibodies against anti-cd19 antibodies.
MX2017001229A (en)EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY.
MX2021003704A (en)Heterodimeric antibodies that bind cd3 and tumor antigens.
PH12018501042A1 (en)Antibodies and antibody fragments for site-specific conjugation
WO2017147383A8 (en)Modified cells for immunotherapy
CL2016002195A1 (en) Car chimeric antigen receptor with antigen binding domains to the constant region of the beta t cell receptor
MX370173B (en)Cs1-specific chimeric antigen receptor engineered immune effector cells.
WO2015092024A3 (en)Method of engineering multi-input signal sensitive t cell for immunotherapy
MY176294A (en)Antibodies comprising chimeric constant domains
PH12017502019A1 (en)Heterodimeric antibodies that bind cd3 and tumor antigens
NZ762750A (en)Anti-hla-a2 antibodies and methods of using the same
PH12015502479B1 (en)Cd19 specific chimeric antigen receptor and uses thereof
MX2016012713A (en)Claudin-6-specific immunoreceptors and t cell epitopes.
AU2016259730A8 (en)Claudin-18.2-specific immunoreceptors and T cell epitopes
MX2015008740A (en)Human igg1 fc region variants and uses thereof.
MX2016017393A (en)Bispecific heterodimeric diabodies and uses thereof.
AU2018338423A1 (en)Novel anti-HLA-A2 antibodies and uses thereof
MX2020000595A (en)Antigen binding regions against fibronectin type iii domains and methods of using the same.
NZ750009A (en)Antibodies comprising chimeric constant domains

Legal Events

DateCodeTitleDescription
FGGrant or registration
[8]ページ先頭
©2009-2025 Movatter.jp